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Introduction
Lutembacher syndrome is a combination of congenital
atrial septal defect (ASD) and acquired mitral stenosis
(MS), which was first described by Lutembacher, a
French physician, in 1916.1 The interatrial shunt decom-
presses the left atrium but increases the pulmonary
blood flow.2,3 Surgical correction has previously been
the treatment of choice. Nowadays however, both
diseases are amenable to percutaneous transcatheter
therapy.4–9 Combined transcatheter therapy was first
described by Ruiz et al in 1992.10 Here, we report 
a case of a patient with Lutembacher syndrome who
benefited from combined transcatheter therapy of bal-
loon valvuloplasty for MS and device closure for ASD
with an Amplatzer septal occluder. To our knowledge,
this is the first reported case in Taiwan.
Case Report
A 28-year-old female came to Taiwan from Indonesia
6 years ago. Her first baby was born smoothly via vagina
5 years ago. She developed breathlessness on exertion,
palpitation, and chest tightness 3 years previously, but
paid it no attention. She was found to have a heart
murmur last year, 3 months into her second pregnancy.
Transthoracic echocardiography revealed moderate MS,
moderate-sized ASD, and dilatation of the right ven-
tricle and both atria. At 36 weeks of pregnancy, she
developed hemoptysis and an induction was carried
out in our cardiac intensive care unit, where she deliv-
ered a 1,990 g female baby. Two months after delivery,
the patient was referred to the department of pedi-
atric cardiology for transcatheter therapy. She had had
several episodes of tonsillitis-associated fever in child-
hood but showed no signs of arthritis, chorea, sub-
cutaneous nodules or erythema marginatum. Physical
examination revealed a grade 3/6 systolic murmur
over the left upper sternal border and a grade 2/6
diastolic murmur over the apex. The lungs were clear
and the liver was impalpable. Exercise capacity was
New York Heart Association class III. Chest radiogram
showed significant cardiomegaly with increased pul-
monary vascularity and a cardiothoracic ratio of 0.65
(Figure 1A). Transesophageal echocardiography showed
a Wilkins score of 8 including mitral valve thickening
(2), reduced leaflet motility (2), subvalvular thicken-
ing (3) and trivial calcification (1).11 The mitral valve
area was 1.49 cm2 using the planimetry method and
2.49cm2 using the Doppler pressure half-time method.
There was trace mitral regurgitation.
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After informed consent was obtained, routine right
and left heart catheterizations were performed. The
pulmonary-to-systemic flow ratio (Qp/Qs) was 5.14
as measured by Fick’s principle. The pulmonary pres-
sure was 56/23 mmHg with a mean of 37 mmHg.
The mean pressure of the left atrium was 23 mmHg.
The mean diastolic pressure gradient across the mitral
valve was 16 mmHg. After a pig-wire was put in the
left atrium, the partially inflated Inoue-balloon (Toray
Marketing & Sales Inc., Houston, TX, USA) could not
be advanced into the left ventricle due to it easily float-
ing back to the right atrium. Therefore, we advanced
a 6 Fr Judkins right catheter into the left ventricle
(Figure 2A) and then placed the pig-wire in the left
ventricle (Figure 2B). At that time, mild hypotension
was noted, but blood pressure returned to normal soon
after the Inoue-balloon catheter was advanced into the
left ventricle and the pig-wire was retracted. The mitral
valve was dilated sequentially with the balloon diame-
ters set at 22, 23 and 24 mm, respectively (Figure 2C).
After valvuloplasty, the mean pressure of the left atrium
decreased to 11 mmHg and the mean diastolic mitral
pressure gradient decreased to 4 mmHg. Rechecked
Qp/Qs decreased to 2.40. The stretched diameter of
the ASD as measured with a sizing plate was 18 mm.
Under intracardiac echocardiographic guidance, the
ASD was closed with a 19-mm Amplatzer septal oc-
cluder as detailed in our previous report (Figure 2D).6
Intracardiac echocardiography revealed no residual
atrial shunt. Transthoracic echocardiography showed
that the mitral valve area was dilated to 2.35 cm2 using
the planimetry method and showed mild mitral regur-
gitation. The patient was discharged uneventfully the
following day. Chest radiogram 1 month later showed
significant improvement of cardiomegaly, with a car-
diothoracic ratio of 0.55 (Figure 1B). There were no
complications during the 4-month follow-up, and the
patient’s exercise capacity improved to New York Heart
Association class II.
Discussion
MS is usually caused by rheumatic fever, which is rare
in developed countries today. In America, a review
paper indicated that MS is most commonly found in
patients who have emigrated from areas where rheu-
matic fever is still endemic.7 It is generally believed 
to be an autoimmune attack of the heart in response
to streptococcal infection.12 Medical management for
patients with MS includes antibiotic prophylaxis for
infective endocarditis and diuretics for mild symp-
toms. When MS is complicated by atrial fibrillation,
rate control and anticoagulation should be started. If
more than mild symptoms exist or asymptomatic pul-
monary hypertension occurs, mechanical relief of MS
is indicated, which includes balloon valvuloplasty, sur-
gical valvuloplasty or valve replacement.7 Although the
presented case had no definite past history of rheumatic
fever, the MS still seemed to be rheumatic because of
characteristic features shown on echocardiography and
migratory history from an endemic area.
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Figure 1. (A) Chest radiogram shows significant cardiomegaly with increased pulmonary vascularity. (B) Chest radiogram 1 month after
transcatheter therapy shows significant improvement of cardiomegaly.
The original case of Lutembacher syndrome was a
61-year-old woman who had been pregnant 7 times.1
Female predominance has been noted in both ASD
and MS, and thus Lutembacher syndrome has a predi-
lection for females. The incidence of MS in patients
with ASD is 4%, and conversely, ASD in patients with
MS is 0.6–0.7%.13 “Iatrogenic” Lutembacher syndrome
refers to patients with MS who have undergone bal-
loon mitral valvuloplasty which created an ASD during
the procedure.14 The incidence of left-to-right atrial
shunts following mitral valvuloplasty is estimated at
11–12%. Most of these ASDs are small and insignificant
hemodynamically.
In Lutembacher syndrome, MS augments the left-
to-right shunt through the ASD while the nonrestric-
tive ASD decompresses the LA, reducing the diastolic
mitral pressure gradient. That means the Doppler pres-
sure half-time method would underestimate the degree
of MS; this occurred in our patient. The planimetry
method yields accurate estimates of mitral valve area
in Lutembacher syndrome.2
Concerning treatment, transcatheter closure of ASD
was first reported by King et al in 1976.4 Since then,
several devices have been developed to close ASDs.
The Amplatzer septal occluder is the first and only
device ever to receive full approval from the United
States Food and Drug Administration for clinical use
in patients with secundum ASD.5,6 Transcatheter bal-
loon mitral valvuloplasty with transseptal technique
has been in development for years. The Inoue-balloon
catheter was introduced in 1984 and was declared to
be the procedure of choice rather than open commis-
surotomy for the treatment of MS in 1998.15 The
balloon was specially designed to be inflated in 2
stages. The distal portion of the balloon inflates first,
and this allows seating of the balloon on the valve.
Further inflation of the proximal portion makes an
hourglass shape. This unique shape centers the balloon
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Figure 2. (A) A 6-Fr Judkins right catheter was advanced into the left ventricle. (B) A pig-wire was placed in the left ventricle. (C) The
mitral valve was dilated with a 24-mm Inoue balloon. (D) Under intracardiac echocardiographic guidance (arrowhead), the atrial septal
defect was closed with a 19-mm Amplatzer septal occluder (arrow).
on the valve and prevents migration when dilating the
mitral valve. These features make it popular for mitral
valvuloplasty.
The combined transcatheter therapy as a rescue pro-
cedure for Lutembacher syndrome was first described
in 1992 by Ruiz et al, who utilized Lock’s clamshell
occluder, mitral and aortic balloon valvotomies.10 They
reported a patient with Lutembacher syndrome and
pulmonary hypertension who received palliative trans-
catheter therapy and died before surgery. Successful
combined transcatheter therapy was first described by
Joseph et al in 1999.16 He used the Amplatzer septal
occluder for ASD and Joseph mitral balloon catheter
for MS. Since then, several successful cases have been
reported.17–19
To our knowledge, this is the first case of a patient
with Lutembacher syndrome who received combined
percutaneous therapy in Taiwan. We used the Inoue
balloon antegradely through an existing ASD to dilate
the stenotic mitral valve and closed the ASD with an
Amplatzer septal occluder. Based on our limited ex-
perience, combined transcatheter therapy of Lutem-
bacher syndrome is safe and effective, with a short
hospital stay and without the complications of open
heart surgery.
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